In Brief

Jury orders McNeil to pay $63M in TEN suit; Marshals seize Globe All Wellness products; USP forms supplement adulteration panel; FDA warnings for GMPs flow; Hurricane Sandy impact knocks GNC revenue; Icahn takes Herbalife stake; U.K. shuts down melatonin ad.

A Massachusetts jury Feb. 13 ordered McNeil-PPC Inc. to pay $63 million to the family of a teenager who suffered toxic epidermal necrolysis after taking Children’s Motrin when she was 7 years old. The amount could exceed $109 million after factoring in a 12% annual interest rate since the case was filed, said a paralegal with the law firm that represented the family. The lawsuit filed in January 2007 against McNeil and parent company Johnson & Johnson alleges the firms were grossly negligent for failing to warn about the known risk of TEN in a manner that consumers could understand. A package insert w the ibuprofen product warns of a less than 1% “probable causal relationship” of developing TEN, according to the suit. A J&J/McNeil spokeswoman said the firm “sympathizes deeply” with the family, which “has suffered a tragedy.” She said TEN is “a very rare condition” and Children’s Motrin when used as directed is safe and effective. J&J has faced similar lawsuits with mixed results, including a case in 2011 in which a jury awarded $10 million to a 13-year-old and her family after she suffered a similar reaction to Children’s Motrin Also see "In Brief" - Pink Sheet, 30 May, 2011..

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Marketing & Advertising

More from Compliance

US FDA’s Advanced Manufacturing Designation Lifts Off With Cellares Cell Shuttle

 

Cellares’ fully automated cell therapy manufacturing platform is the first system to receive an Advanced Manufacturing Technology designation from US FDA

Pharma Still Nervous While Riding Trump’s Tariff Rollercoaster

 

The rollout of Trump’s plan has been a policy whiplash, but despite a 90-day pause on tariffs, the US president still appears to be holding a grudge with industry over drug pricing.

Pipeline To Product – What Is Driving Cell And Gene Therapy Progress In India?

 
• By 

US-based Colossal Labs has claimed to bring back the dire wolf from extinction. While the science is not as dramatic in India yet, cell and gene therapies are making progress as treatments for cancer and other diseases. Pink Sheet takes a look at what is driving CGT success and growth.